Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartﾒs recombinant…
Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
Altimmune added Lonza as manufacturing partner for supply of AdCOVIDﾙ vaccine candidate for COVID-19
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDﾙ, Altimmuneﾒs next-generation, single-dose…
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
Fred Hutch began experimental COVID-19 vaccine efficacy trial
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
ImmunityBioﾒs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2
On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine
On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…
Biotechnology | COVID-19 | Medicine | NIH | Therapeutics | Vaccine
Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in Vietnam
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…
Novavax announced facility expansion to support global vaccine development
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
CureVac reported positive interim phase 1 data for COVID-19 vaccine candidate
On Nov. 2, 2020, CureVac announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the…
Kaiser Permanente Research Institute enrolled volunteers in a phase 3 clinical trial to evaluate COVID-19 vaccine
On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…
Trials of University of Oxford’s Coronavirus vaccine began in Kenya
On Oct. 30, 2020, the University of Oxford announced that Kenya had joined the global efforts in search…
Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new funding
On Oct. 30, 2020, Icosavax announced the launch of the companyﾒs COVID-19 vaccine program with preclinical data on…
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
Entos Pharma awarded $5 million in NRC IRAP funding to conduct phase I Clinical trial of COVID-19 DNA vaccine
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…
CureVac reported positive preclinical data for its COVID-19 vaccine candidate CVnCoV
On Oct. 23, 2020, CureVac announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in…
FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
Johnson & Johnson prepared to resume phase 3 ENSEMBLE trial of COVID-19 vaccine candidate in the US
On Oct. 23, 2020, Johnson & Johnson announced that it was preparing to resume recruitment in the pivotal…
Oxford Immunotec selected as sole supplier of UK T cell testing for SARS-CoV-2 COVID vaccine trials
On Oct. 22, 2020, Oxford Immunotec announced that it had been selected to provide T cell testing to…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…